Qritive, a leading healthcare AI firm, has announced a $7.5M investment round headed by MassMutual Ventures and supported by SEEDS Capital and Exfinty Venture Partners. Qritive will use the new funds to expand geographically, increase its product portfolio, and assist regulatory clearances.
Qritive, which was founded in 2017 by Dr Aneesh Sathe and Dr Kaveh Taghipour, now has offices in Singapore, the United States, and India. Qritive solutions use artificial intelligence to give fast and precise interpretations of pathology entire slide image scans in seconds, shortening time to treatment and enhancing accuracy for cancer care.
Qritive’s products are CE certified and clinically authorised by the Singapore Health Sciences Authority (HSA). Qritive’s technology aids in the diagnosis of numerous cancer types, including colon, prostate, lymph node, and breast cancer, and contains a comprehensive range of immunohistochemical capabilities.
The Pantheon digital pathology platform from Qritive is a one-of-a-kind platform that combines features for case administration, reporting, slide viewing and analysis, telepathology, synoptic reporting, and LIS integration. Qritive intends to build an open-pathology environment, whereas Pantheon is independent of microscopy and IT, allowing for easy integration of third-party AI solutions.
“The prevalence of cancer is rising globally, and by 2030, Asia will account for nearly half of all cancer cases worldwide. Speed and accuracy are of utmost importance, especially in the backdrop of a severe pathologist shortage. The clinical-grade AI-powered technology from Qritive transforms diagnosis to NextGen by being disruptive, accurate, removing the existing bottlenecks, and supporting pathologists at every stage.”, Chinnu Senthilkumar, Managing Partner at Exfinity Venture Partners.
“Qritive’s platform digitizes and streamlines the pathology workflow from end-to-end, supporting clinicians with a wide range of tools – including image analysis, case management, and reporting modules. With an international network of pathologists, Qritive is uniquely positioned to accelerate the adoption of digital pathology across the globe. We look forward to supporting Qritive’s growth and the meaningful work that it is doing to improve patient outcomes.” – Ryan Collins, Managing Director at MassMutual Ventures.”